SCHEMBL12445964

SCHEMBL12445964

CCOC(=O)NCCCCCCCC=O

nearest known ligand 0.58

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ACHE P22303 14/20 0.49
EPHX2 P34913 2/20 0.48
EPHX1 P07099 1/20 0.47
MAPT P10636 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12417367 0.87 ACHE (0.61) ACHEEPHX1
SCHEMBL7781306 0.87 ACHE (0.61) ACHEEPHX1
SCHEMBL27712904 0.87 ACHE (0.61) ACHEEPHX1
SCHEMBL1023071 0.87 ACHE (0.61) ACHEEPHX1
SCHEMBL16486265 0.85 ACHE (0.44) ACHEMAPT
SCHEMBL8811962 0.85 ACHE (0.67) ACHEEPHX2EPHX1
SCHEMBL7440478 0.85 ACHE (0.67) ACHEEPHX2EPHX1
SCHEMBL7570219 0.84 ACHE (0.61) ACHEEPHX1
SCHEMBL11492351 0.84 ACHE (0.47) ACHEEPHX2EPHX1
SCHEMBL15109213 0.84 ACHE (0.47) ACHEEPHX2EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9763995-B2 Polymer conjugates of protegrin peptides NEKTAR THERAPEUTICS (US) 2017-09-19 US disclosed
US-20160158311-A1 POLYMER CONJUGATES OF PROTEGRIN PEPTIDES NEKTAR THERAPEUTICS 2016-06-09 US disclosed
US-8722732-B2 Oligomer-calcimimetic conjugates and related compounds NEKTAR THERAPEUTICS (US) 2014-05-13 US disclosed
US-20120238621-A1 Oligomer-Calcimimetic Conjugates and Related Compounds NEKTAR THERAPEUTICS (US) 2012-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160158311-A1 POLYMER CONJUGATES OF PROTEGRIN PEPTIDES PSMG3, PSMB11, UBQLN1 ACHE 4515/4885EPHX2 3396/4885EPHX1 3817/4885
US-20120238621-A1 Oligomer-Calcimimetic Conjugates and Related Compounds CALCR, CALCB, CALCA ACHE 2086/4885EPHX2 835/4885EPHX1 2416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.